Recurrent suicidal ideations in patients with overweight or obesity within 6-month follow-up time window (comparison between propensity-score matched groups)

Population	Semaglutide group	Non-GLP1R agonist anti-obesity medications group	o	HR (95% CI)
Overall (n = 865/group)	6.5% (56)	14.1% (122)	-	0.44 (0.32–0.60)
Women (n = 618/group)	6.5% (40)	12.8% (79)		0.49 (0.34–0.72)
Men (n = 234/group)	7.3% (17)	20.1% (47)	├ ■-	0.33 (0.19–0.57)
age <= 45 years (n = 446/group)	6.7% (30)	17.3% (77)	-	0.38 (0.25–0.57)
age > 45 years (n = 409/group)	6.4% (26)	12.7% (52)		0.47 (0.30–0.76)
			0.10 0.20 0.40 0.80 2.0 Hazard Ratio (H F	4.0 8.00 R)